Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for MSI-High Colorectal Cancer
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
In the ever-evolving landscape of cancer biology, one molecular pathway has captivated researchers due to its pivotal role in maintaining ...
A recently published study has uncovered a significant shortfall in the genetic testing of patients diagnosed with endometrial cancer—commonly referred ...
In a groundbreaking study recently published in Nature Communications, a team of researchers led by Weijers, D.D., Hinić, S., and ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine